

Amado AndrÃ©s

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7294602/publications.pdf>

Version: 2024-02-01

165
papers

4,329
citations

101543

36
h-index

133252

59
g-index

167
all docs

167
docs citations

167
times ranked

5290
citing authors

#	ARTICLE	IF	CITATIONS
1	Fluconazole versus micafungin for initial antifungal prophylaxis against <i>Candida</i> in pancreas transplant recipients: A comparative study of two consecutive periods. <i>Mycoses</i> , 2022, 65, 517-525.	4.0	2
2	Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events. <i>Atherosclerosis Plus</i> , 2022, 48, 37-46.	0.7	1
3	Malignancies in Deceased Organ Donors: The Spanish Experience. <i>Transplantation</i> , 2022, 106, 1814-1823.	1.0	7
4	Human pegivirus type 1 infection in kidney transplant recipients: Replication kinetics and clinical correlates. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	3
5	MO976: Recurrence of Immune Complex And Complement-Mediated Membranoproliferative Glomerulonephritis in Kidney Transplantation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	1
6	SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19.. <i>Transplantation</i> , 2021, Publish Ahead of Print, 1372-1380.	1.0	17
7	CMV infection, valganciclovir exposure, and the risk of BK viremia and associated nephropathy after kidney transplantation: Is there a link?. <i>Transplant Infectious Disease</i> , 2021, 23, e13597.	1.7	2
8	Detection of BK polyomavirus genotypes to predict the development of BK polyomavirus-associated complications in kidney transplant recipients: A retrospective analysis. <i>Transplant Infectious Disease</i> , 2021, 23, e13615.	1.7	4
9	Efficacy and Safety of Oral Fosfomicin for Asymptomatic Bacteriuria in Kidney Transplant Recipients: Results from a Spanish Multicenter Cohort. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	4
10	Long-term plasmapheresis therapy in the management of focal segmental glomerulosclerosis recurrence after kidney transplantation. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103046.	1.0	0
11	Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. <i>American Journal of Transplantation</i> , 2021, 21, 2573-2582.	4.7	53
12	Improved short-term outcomes of kidney transplants in controlled donation after the circulatory determination of death with the use of normothermic regional perfusion. <i>American Journal of Transplantation</i> , 2021, 21, 3618-3628.	4.7	46
13	Pericarditis secondary to COVID-19 infection in a kidney transplant recipient. <i>Nefrología</i> , 2021, 41, 349-351.	0.4	3
14	Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3946-3957.	4.7	5
15	Cytomegalovirus Exposure and the Risk of Overall Infection After Kidney Transplantation: A Cohort Study on the Indirect Effects Attributable to Viral Replication. <i>Transplant International</i> , 2021, 35, 10273.	1.6	1
16	Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients. <i>Transplantation Direct</i> , 2021, 7, e794.	1.6	28
17	Microangiopatía trombótica como recidiva de síndrome antifosfolípido en trasplante renal. <i>Nefrología</i> , 2020, 40, 108-110.	0.4	0
18	Oral fosfomicin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort. <i>American Journal of Transplantation</i> , 2020, 20, 451-462.	4.7	15

#	ARTICLE	IF	CITATIONS
19	Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients – a single centre cohort study. <i>Transplant International</i> , 2020, 33, 402-413.	1.6	11
20	Early kinetics of Torque Teno virus DNA load and BK polyomavirus viremia after kidney transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13240.	1.7	16
21	Tocilizumab use in Kidney Transplant Patients with COVID-19. <i>Clinical Transplantation</i> , 2020, 34, e14072.	1.6	19
22	SARS-CoV-2 Infection in Hospitalized Patients With Kidney Disease. <i>Kidney International Reports</i> , 2020, 5, 905-909.	0.8	57
23	Imbalance favoring follicular helper T cells over IL10+ regulatory B cells is detrimental for the kidney allograft. <i>Kidney International</i> , 2020, 98, 732-743.	5.2	13
24	A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score. <i>Journal of Infectious Diseases</i> , 2020, 222, 479-487.	4.0	2
25	Kidney transplantation in the extremely elderly from extremely aged deceased donors: a kidney for each age. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 687-696.	0.7	14
26	Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon- γ release assay in kidney transplant recipients treated with antithymocyte globulin. <i>American Journal of Transplantation</i> , 2020, 20, 2070-2080.	4.7	30
27	Variations in Circulating Active MMP-9 Levels during Renal Replacement Therapy. <i>Biomolecules</i> , 2020, 10, 505.	4.0	3
28	COVID-19 in solid organ transplant recipients: A single-center case series from Spain. <i>American Journal of Transplantation</i> , 2020, 20, 1849-1858.	4.7	358
29	Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. <i>Transplantation</i> , 2020, 104, 2599-2608.	1.0	8
30	Longitudinal profile of circulating T follicular helper lymphocytes parallels anti-HLA sensitization in renal transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 89-97.	4.7	48
31	Kidney transplant from uncontrolled donation after circulatory death donors maintained by nECMO has long-term outcomes comparable to standard criteria donation after brain death. <i>American Journal of Transplantation</i> , 2019, 19, 434-447.	4.7	39
32	Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. <i>Clinical Microbiology and Infection</i> , 2019, 25, 381.e1-381.e10.	6.0	32
33	115.7: DTI Foundation collaboration with China: An educational and cooperation program.. <i>Transplantation</i> , 2019, 103, S4-S5.	1.0	0
34	Uncontrolled donation after circulatory death. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 358-363.	1.6	15
35	Low 25-hydroxyvitamin D Levels and the Risk of Late CMV Infection After Kidney Transplantation: Role for CMV-specific Mediated Immunity. <i>Transplantation</i> , 2019, 103, e216-e217.	1.0	3
36	Kidney transplantation from donors after uncontrolled circulatory death: the Spanish experience. <i>Kidney International</i> , 2019, 95, 420-428.	5.2	43

#	ARTICLE	IF	CITATIONS
37	Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1139-1149.	4.7	57
38	Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?. <i>Atherosclerosis</i> , 2018, 269, 204-210.	0.8	2
39	Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. <i>Transplant International</i> , 2018, 31, 887-899.	1.6	31
40	Fabry Nephropathy: An Evidence-Based Narrative Review. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 406-421.	2.0	35
41	Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation. <i>Clinical Microbiology and Infection</i> , 2018, 24, 192-198.	6.0	25
42	Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2018, 3, 122-132.	0.8	6
43	Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study. <i>Transplant International</i> , 2018, 31, 187-197.	1.6	12
44	Association between baseline serum hepcidin levels and infection in kidney transplant recipients: Potential role for iron overload. <i>Transplant Infectious Disease</i> , 2018, 20, e12807.	1.7	9
45	FP723RESULTS OF KIDNEY TRANSPLANTATION IN VERY OLD RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i290-i290.	0.7	0
46	The Use of Sofosbuvir (SOF)-containing Direct Antiviral Agents (DAA)-based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection. <i>Transplantation</i> , 2018, 102, S228.	1.0	0
47	Successful Treatment of BK Nephropathy with Tacrolimus and mTOR Inhibitors. <i>Transplantation</i> , 2018, 102, S327.	1.0	0
48	FP712KIDNEY TRANSPLANTATION FROM UNCONTROLLED DONATION AFTER CIRCULATORY DEATH AFTER 10 YEAR OF FOLLOW-UP. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i285-i286.	0.7	0
49	SP753MALIGNANCY COMPLICATIONS AFTER KIDNEY TRANSPLANTATION, SHOULD WE USE INDUCTION THERAPY?. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i602-i602.	0.7	0
50	Results of Kidney Transplantation in Very Old Age Recipients Using Kidneys from Very Old Donors. <i>Transplantation</i> , 2018, 102, S159.	1.0	0
51	Helper Innate Lymphoid Cells (hILC) resist Immunosuppressive Therapy. <i>Transplantation</i> , 2018, 102, S283-S284.	1.0	0
52	Continuous Training of Critical Care Professional to Increase Organ Donation Rates in Yunnan Province and Guangxi Autonomous Region in China. <i>Transplantation</i> , 2018, 102, S810.	1.0	0
53	Kidney Transplantation from Uncontrolled Donation after Circulatory Death, our Outcomes Compared to Donation after Brain Death after Very Long Time. <i>Transplantation</i> , 2018, 102, S413.	1.0	2
54	Cardiovascular Disease after Kidney Transplant from Uncontrolled Donation after Circulatory Death (uDCD). <i>Transplantation</i> , 2018, 102, S84.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Different Patterns of Risk Factors for Mortality according Recipient Age after Renal Transplantation. A Multicenter and Prospective Study at Ten Years in the Clinical Practice. <i>Transplantation</i> , 2018, 102, S191.	1.0	0
56	Malignancy Complications after Kidney Transplantation with Different Immunosuppression Induction Protocols. <i>Transplantation</i> , 2018, 102, S348.	1.0	0
57	Chronic Hypotension in Dialysis is a Prognostic Factor in the Evolution of Kidney Transplantation. <i>Transplantation</i> , 2018, 102, S529.	1.0	0
58	SP167RECURRENT OF MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i400-i400.	0.7	0
59	Vitamin D deficiency and infection risk in kidney transplant recipients: A single-center cohort study. <i>Transplant Infectious Disease</i> , 2018, 20, e12988.	1.7	7
60	Analysis of the Incidence of Brain Death per Functioning Ventilator in the Intensive Care Units of a General Hospital. <i>Transplantation</i> , 2018, 102, S806.	1.0	0
61	Rituximab does not Prevent Focal and Segmental Glomerulosclerosis Recurrence after Renal Transplantation in Patients at Risk. <i>Transplantation</i> , 2018, 102, S9.	1.0	0
62	Pretransplant IgA-Anti-Beta 2 Glycoprotein I Antibodies As a Predictor of Early Graft Thrombosis after Renal Transplantation in the Clinical Practice: A Multicenter and Prospective Study. <i>Frontiers in Immunology</i> , 2018, 9, 468.	4.8	13
63	The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti- β -2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation. <i>Transplantation</i> , 2017, 101, 597-607.	1.0	34
64	Serum $\text{scD} > 30$: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12668.	1.7	13
65	Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain. <i>Transplant Infectious Disease</i> , 2017, 19, e12623.	1.7	8
66	PREFiNe project: strategic plan to improve knowledge & recognition of Fabry disease among Spanish nephrologists. <i>Molecular Genetics and Metabolism</i> , 2017, 120, S41.	1.1	1
67	Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options. <i>Transplant Infectious Disease</i> , 2016, 18, 575-584.	1.7	44
68	Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study. <i>American Journal of Transplantation</i> , 2016, 16, 3220-3234.	4.7	57
69	Pre-transplant dialysis modality does not influence short- or long-term outcome in kidney transplant recipients: analysis of paired kidneys from the same deceased donor. <i>Clinical Transplantation</i> , 2016, 30, 1097-1107.	1.6	21
70	Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case-Control Study. <i>American Journal of Transplantation</i> , 2016, 16, 2148-2157.	4.7	39
71	Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. <i>American Journal of Transplantation</i> , 2016, 16, 2943-2953.	4.7	104
72	Monitoring of intracellular adenosine triphosphate in CD4 ⁺ T cells to predict the occurrence of cytomegalovirus disease in kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 1094-1105.	1.6	11

#	ARTICLE	IF	CITATIONS
73	Immune risk phenotype in kidney transplant recipients: a reliable surrogate for premature immune senescence and increased susceptibility to infection?. <i>Transplant Infectious Disease</i> , 2016, 18, 968-970.	1.7	10
74	Influence of Age and HLA Alleles on the CMV-Specific Cell-Mediated Immunity Among CMV-Seropositive Kidney Transplant Candidates. <i>American Journal of Transplantation</i> , 2015, 15, 2525-2526.	4.7	8
75	Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R ⁻ solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 637-646.	1.7	20
76	SP840RELATIONSHIP BETWEEN PRE-TRANSPLANT BODY COMPOSITION AND RENAL POST-TRANSPLANT EVOLUTION. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii654-iii654.	0.7	0
77	Effect of delaying prophylaxis against CMV in D+/R ⁻ solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease. <i>Journal of Infection</i> , 2015, 71, 561-570.	3.3	11
78	Impact of Left Ventricular Dysfunction on Renal Transplant Survival: Study of Paired Kidneys From the Same Donor. <i>Transplantation Proceedings</i> , 2015, 47, 70-72.	0.6	8
79	Potential role of post-transplant hypogammaglobulinemia in the risk of <i>Clostridium difficile</i> infection after kidney transplantation: a case-control study. <i>Infection</i> , 2015, 43, 413-422.	4.7	14
80	Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to Î² 2-Glycoprotein I. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 735-745.	6.1	31
81	Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2015, 17, 314-321.	1.7	6
82	Preemptive kidney transplantation in elderly recipients with kidneys discarded of very old donors: A good alternative. <i>Nefrologia</i> , 2015, 35, 246-255.	0.4	8
83	Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. <i>Transplant International</i> , 2014, 27, 674-685.	1.6	65
84	Assessing the Risk of De Novo Malignancy in Kidney Transplant Recipients. <i>Transplantation</i> , 2014, 98, e36-e37.	1.0	4
85	Enterococcal infection in kidney transplant recipients in a setting of low prevalence of vancomycin resistance. <i>Transplant Infectious Disease</i> , 2014, 16, 692-695.	1.7	1
86	Should IFN-Î³, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. <i>Clinical Immunology</i> , 2014, 154, 141-154.	3.2	55
87	Donation after cardiac death: results of the <sc>SUMMA</sc> 112 â€“ <sc>H</sc>ospital 12 de <sc>O</sc>ctubre <sc>P</sc>rogram. <i>Clinical Transplantation</i> , 2013, 27, 283-288.	1.6	16
88	Infection Risk in Kidney Transplantation From Uncontrolled Donation After Circulatory Death Donors. <i>Transplantation Proceedings</i> , 2013, 45, 1335-1338.	0.6	8
89	Serum iron parameters in the early post-transplant period and infection risk in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2013, 15, 600-611.	1.7	12
90	Hypocomplementemia in Kidney Transplant Recipients: Impact on the Risk of Infectious Complications. <i>American Journal of Transplantation</i> , 2013, 13, 685-694.	4.7	33

#	ARTICLE	IF	CITATIONS
91	High incidence of delayed graft function in HIV-infected kidney transplant recipients. <i>Transplant International</i> , 2013, 26, 893-902.	1.6	21
92	Epidemiology, risk factors and impact on long-term pancreatic function of infection following pancreas-kidney transplantation. <i>Clinical Microbiology and Infection</i> , 2013, 19, 1132-1139.	6.0	42
93	Epstein-Barr Virus DNAemia Is an Early Surrogate Marker of the Net State of Immunosuppression in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2013, 95, 688-693.	1.0	18
94	Harmful Effect of Preformed Anti-MICA Antibodies on Renal Allograft Evolution in Early Posttransplantation Period. <i>Transplantation</i> , 2013, 96, 70-78.	1.0	28
95	The impact of darbepoetin alfa in early post-transplant anaemia management: retrospective exploratory study. <i>Nefrologia</i> , 2013, 33, 107-15.	0.4	0
96	Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv39-iv46.	0.7	85
97	Renal Transplantation from Donors with a Positive Serology for Hepatitis C. <i>Contributions To Nephrology</i> , 2012, 176, 117-129.	1.1	5
98	Non-Heart Beating Donor Kidney Transplantation Is not Associated with An Increased Risk of Post-Transplant Infection. <i>Transplantation</i> , 2012, 94, 552.	1.0	0
99	The Impact of High Steroid Doses in Patients with Post- Transplant Membranous Glomerulonephritis Associated or not with Hepatitis C Virus Infection. <i>Transplantation</i> , 2012, 94, 918.	1.0	0
100	Renal Function and NODM in <i>De Novo</i> Renal Transplant Recipients Treated with Standard and Reduced Levels of Tacrolimus in Combination with EC-MPS. <i>Journal of Transplantation</i> , 2012, 2012, 1-9.	0.5	12
101	Monitoring of Immunoglobulin Levels Identifies Kidney Transplant Recipients at High Risk of Infection. <i>American Journal of Transplantation</i> , 2012, 12, 2763-2773.	4.7	66
102	mTOR inhibitor-associated proteinuria in kidney transplant recipients. <i>Transplantation Reviews</i> , 2012, 26, 27-29.	2.9	65
103	Enteric-coated mycophenolate sodium in <i>de novo</i> and maintenance kidney-pancreas transplant recipients. <i>Clinical Transplantation</i> , 2012, 26, 424-431.	1.6	4
104	2197 NON-HEART-BEATING DONORS (TYPE I AND II MAASTRICHT CATEGORY): RESULTS OF OUR PROGRAM. <i>Journal of Urology</i> , 2011, 185, .	0.4	0
105	Should we be using kidneys from hepatitis C virus-infected donors?. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 599-604.	2.0	6
106	Kidney Transplantation Outcomes in HIV Infection: The European Experience. <i>American Journal of Transplantation</i> , 2011, 11, 635-636.	4.7	8
107	Acute graft pyelonephritis in renal transplant recipients: incidence, risk factors and long-term outcome. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1065-1073.	0.7	77
108	HIV infection and renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1401-1407.	0.7	55

#	ARTICLE	IF	CITATIONS
109	Treatment with calcimimetics in kidney transplantation. <i>Transplantation Reviews</i> , 2010, 24, 79-88.	2.9	17
110	Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients. <i>American Journal of Transplantation</i> , 2010, 10, 2453-2462.	4.7	96
111	Renal transplantation in patients with hepatitis C virus antibody. A long national experience. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, ii41-ii46.	2.9	18
112	Results of renal re-transplant in Spain (1990-2002). <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, ii37-ii40.	2.9	0
113	Extended-Release Tacrolimus Therapy in De Novo Kidney Transplant Recipients: Single-Center Experience. <i>Transplantation Proceedings</i> , 2010, 42, 3034-3037.	0.6	16
114	Cardiovascular Events After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 2981-2983.	0.6	15
115	Addition of Spironolactone to Dual Blockade of Renin Angiotensin System Dramatically Reduces Severe Proteinuria in Renal Transplant Patients: An Uncontrolled Pilot Study at 6 Months. <i>Transplantation Proceedings</i> , 2010, 42, 2899-2901.	0.6	31
116	Results of a Living Donor Kidney Promotion Program. <i>Transplantation Proceedings</i> , 2010, 42, 2837-2838.	0.6	9
117	Systematic screening and treatment of asymptomatic bacteriuria in renal transplant recipients. <i>Kidney International</i> , 2010, 78, 774-781.	5.2	113
118	A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. <i>Clinical Transplantation</i> , 2009, 23, 23-32.	1.6	13
119	A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R ⁺) solid organ transplant recipients. <i>Clinical Transplantation</i> , 2009, 23, 666-671.	1.6	16
120	Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2009, 11, 400-404.	1.7	9
121	Renal Transplantation in Emigrants From Africa in Spain: Similar Results but Different Infectious Profile Compared With Spanish People. <i>Transplantation Proceedings</i> , 2009, 41, 2363-2365.	0.6	5
122	Peripheral Blood Regulatory T Cells in Long-Term Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2009, 41, 2360-2362.	0.6	11
123	Lower Rate of Family Refusal for Organ Donation in Non-Heart-Beating Versus Brain-Dead Donors. <i>Transplantation Proceedings</i> , 2009, 41, 2304-2305.	0.6	33
124	Urological Complications After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 2457-2459.	0.6	17
125	Kidneys From Elderly Deceased Donors Discarded for Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 2379-2381.	0.6	12
126	Clinical Implications of Proteinuria in Renal Transplant Recipients Switching to Rapamycin for Chronic Allograft Dysfunction. <i>Transplantation Proceedings</i> , 2009, 41, 2348-2350.	0.6	12

#	ARTICLE	IF	CITATIONS
127	Compative Study of Bladder Versus Enteric Drainage in Pancreas Transplantation. Transplantation Proceedings, 2009, 41, 2466-2468.	0.6	18
128	Relaparotomy After Pancreas Transplantation: Causes and Outcomes. Transplantation Proceedings, 2009, 41, 2472-2474.	0.6	52
129	Survival of Patients Older Than 60 Years With Kidneys Transplanted From Spanish Expanded Criteria Donors Versus Patients Continued on Hemodialysis. Transplantation Proceedings, 2009, 41, 2376-2378.	0.6	11
130	RENAL TRANSPLANT IN EXTREMELY OLD RECEPTORS. Journal of Urology, 2009, 181, 808-809.	0.4	42
131	A Randomized Trial Comparing Renal Function in Older Kidney Transplant Patients Following Delayed Versus Immediate Tacrolimus Administration. Transplantation, 2009, 88, 1101-1108.	1.0	45
132	Influence of Dialysis Modality on Complications and Patient and Graft Survival After Pancreas-Kidney Transplantation. Transplantation Proceedings, 2008, 40, 2999-3000.	0.6	15
133	Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney International, 2008, 74, S94-S99.	5.2	46
134	Efficacy and Safety of Valsartan, an Angiotensin II Receptor Antagonist, in Hypertension After Renal Transplantation: A Randomized Multicenter Study. Transplantation Proceedings, 2006, 38, 2419-2423.	0.6	23
135	Posttransplant Diabetes Mellitus in Renal Allograft Recipients: A Prospective Multicenter Study at 2 Years. Transplantation Proceedings, 2006, 38, 3530-3532.	0.6	21
136	Valganciclovir Preemptive Therapy for the Prevention of Cytomegalovirus Disease in High-Risk Seropositive Solid-Organ Transplant Recipients. Transplantation, 2006, 82, 30-35.	1.0	45
137	Ischemic Heart Disease after Renal Transplantation in Patients on Cyclosporine in Spain. Journal of the American Society of Nephrology: JASN, 2006, 17, S286-S290.	6.1	20
138	Cancer incidence after immunosuppressive treatment following kidney transplantation. Critical Reviews in Oncology/Hematology, 2005, 56, 71-85.	4.4	115
139	Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney International, 2005, 68, 263-270.	5.2	117
140	Anti-CD25 Monoclonal Antibody Sequential Immunosuppressive Induction Therapy in Renal Transplants With High Risk of Delayed Graft Function. Transplantation Proceedings, 2005, 37, 3736-3737.	0.6	8
141	Comparison of Cytomegalovirus Viral Load Measure by Real-Time PCR With pp65 Antigenemia for the Diagnosis of Cytomegalovirus Disease in Solid Organ Transplant Patients. Transplantation Proceedings, 2005, 37, 4094-4096.	0.6	27
142	A disproportionately greater body weight of the recipient in regards to the donor causes chronic graft nephropathy. A study of paired kidneys. Nephrology Dialysis Transplantation, 2004, 19, iii21-iii25.	0.7	3
143	Results of kidney transplantation in recipients over 70 years of age: experience at a single center. Transplantation Proceedings, 2003, 35, 1675-1676.	0.6	14
144	Helical computed tomography angiography is the most efficient test to assess vascular calcifications in the iliac arterial sector in renal transplant candidates. Transplantation Proceedings, 2003, 35, 1682-1683.	0.6	19

#	ARTICLE	IF	CITATIONS
145	Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications. <i>Transplantation Proceedings</i> , 2002, 34, 96.	0.6	2
146	Use of kidneys from anti-HCV positive donors. <i>Transplantation Proceedings</i> , 2001, 33, 1776-1777.	0.6	8
147	Fibrosing cholestatic hepatitis-like syndrome in hepatitis B virus-negative and hepatitis C virus-negative renal transplant recipients. <i>American Journal of Kidney Diseases</i> , 2001, 38, 640-645.	1.9	11
148	Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. <i>Clinical Transplantation</i> , 2000, 14, 110-114.	1.6	27
149	Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria. <i>American Journal of Kidney Diseases</i> , 2000, 35, 141-145.	1.9	28
150	Policies concerning the use of kidneys from donors infected with hepatitis C virus. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 71-73.	0.7	27
151	The early impact of mycophenolate mofetil in combination with steroids and cyclosporine neoral after renal transplantation: a six-month analysis. <i>Transplantation Proceedings</i> , 1999, 31, 2265-2266.	0.6	2
152	Glomerulonephritis associated with hepatitis C virus infection. <i>Current Opinion in Nephrology and Hypertension</i> , 1999, 8, 205-211.	2.0	23
153	Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. <i>Kidney International</i> , 1998, 54, 915-920.	5.2	46
154	Hepatitis C virus and renal transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 177-184.	2.0	29
155	Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 511-515.	2.0	55
156	Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. <i>Kidney International</i> , 1995, 47, 1419-1425.	5.2	168
157	Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. <i>Kidney International</i> , 1995, 47, 236-240.	5.2	104
158	Effects of Body-Weight Loss and Captopril Treatment on Proteinuria Associated with Obesity. <i>Nephron</i> , 1995, 70, 35-41.	1.8	128
159	Immunosuppression induced by hepatitis C virus infection reduces acute renal-transplant rejection. <i>Lancet, The</i> , 1995, 346, 1497-1498.	13.7	50
160	Idiopathic dialysis ascites in the nineties: Resolution after renal transplantation. <i>American Journal of Kidney Diseases</i> , 1995, 26, 668-670.	1.9	5
161	Long-Term Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Patients With Nephrotic Proteinuria. <i>American Journal of Kidney Diseases</i> , 1992, 20, 240-248.	1.9	133
162	Acute renal failure after liver transplantation in patients treated with cyclosporine. <i>Transplantation Proceedings</i> , 1992, 24, 126-7.	0.6	18

#	ARTICLE	IF	CITATIONS
163	Nephrotic Proteinuria Without Hypoalbuminemia: Clinical Characteristics and Response to Angiotensin-Converting Enzyme Inhibition. American Journal of Kidney Diseases, 1991, 17, 330-338.	1.9	75
164	Tubular Dysfunction in Nephrotic Syndrome: Incidence and Prognostic Implications. Nephrology Dialysis Transplantation, 1991, 6, 683-688.	0.7	7
165	Hematuria due to hypercalciuria and hyperuricosuria in adult patients. Kidney International, 1989, 36, 96-99.	5.2	62